| Phase 16 trials |
|
Phase 1
|
NCT07067775 |
Aug 2025 |
acute coronary syndrome |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05651074 |
Nov 2022 → Feb 2023 |
— |
Jiangsu vcare pharmaceutical technology co., LTD |
Unknown
|
No outcome recorded
|
|
Phase 1
|
NCT05162053 |
Dec 2021 → Nov 2022 |
acute coronary syndrome |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04919551 |
Aug → Oct 2021 |
acute coronary syndrome |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT04143750 |
Nov → Dec 2019 |
— |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03942458 |
Apr → Jun 2019 |
— |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
| Phase 21 trial |
|
Phase 2
|
NCT03599284 |
Aug 2018 → Jun 2019 |
coronary atherosclerosis |
Jiangsu vcare pharmaceutical technology co., LTD |
Completed
|
No outcome recorded
|
| Phase 31 trial |
|
Phase 3
|
NCT06577519 |
Sep 2024 → Dec 2026 expected |
acute coronary syndrome |
Jiangsu vcare pharmaceutical technology co., LTD |
Recruiting
|
No outcome recorded
|